Tetra Bio-Pharma (DB:JAM1) - Hisse Senedi Fiyatı, Haberler ve Analizler

JAM1 Stoklara Genel Bakış

A biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology.

Şirket hakkında

JAM1 temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	0/6
Temettüler	0/6

Ödüller

Risk Analizi

Kazançlar son 5 yılda yılda 42.8% oranında azaldı

Anlamlı bir piyasa değeri yok ( €13M )

Geliri 1 milyon ABD dolarından az ( CA$0 )

Negatif hissedar öz sermayesi

+ 3 daha fazla risk

Tetra Bio-Pharma Inc. Rakipler

Biofrontera

XTRA:B8FK

€17.0m

SynBiotic

DUSE:SBX

€31.9m

Cantourage Group

XTRA:HIGH

€57.4m

Redx Pharma

DB:0RX

€65.0m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Tetra Bio-Pharma
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	CA$0.013
52 Haftanın En Yüksek Seviyesi	CA$0.065
52 Haftanın En Düşük Seviyesi	CA$0.0046
Beta	2.26
11 Aylık Değişim	0%
3 Aylık Değişim	-0.79%
1 Yıllık Değişim	-59.28%
33 Yıllık Değişim	-92.13%
5 Yıllık Değişim	-97.16%
Halka arzdan bu yana değişim	-72.83%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	JAM1	DE Pharmaceuticals	DE Pazar
7D	0%	-2.8%	0.02%
1Y	-59.3%	-6.7%	19.6%

Getiri vs. Endüstri: JAM1 geçen yıl % -11.1 oranında getiri sağlayan German Pharmaceuticals sektörünün gerisinde kaldı.

Getiri vs Piyasa: JAM1 geçen yıl % 13.8 oranında getiri sağlayan German Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is JAM1's price volatile compared to industry and market?
JAM1 volatility
JAM1 Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	7.6%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.4%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: JAM1 son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: JAM1 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
n/a	33	Guy Chamberland	www.tetrabiopharma.com

Tetra Bio-Pharma Inc. Temel Bilgiler Özeti

Tetra Bio-Pharma'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
JAM1 temel i̇stati̇sti̇kler
Piyasa değeri	€8.97m
Kazançlar(TTM)	-€27.15m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-0.3x

F/K Oranı

JAM1 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
JAM1 gelir tablosu (TTM)
Gelir	CA$0
Gelir Maliyeti	CA$0
Brüt Kâr	CA$0
Diğer Giderler	CA$39.02m
Kazançlar	-CA$39.02m

Son Raporlanan Kazançlar

Aug 31, 2022

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.076
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	-28.1%

JAM1 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

JAM1 Stoklara Genel Bakış

Ödüller

Risk Analizi

Tetra Bio-Pharma Inc. Rakipler

XTRA:B8FK

€17.0m

DUSE:SBX

€31.9m

XTRA:HIGH

€57.4m

DB:0RX

€65.0m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Tetra Bio-Pharma Inc. Provides Its Shareholders with Another Regulatory Update on the REDUVO™ New Drug Submission

Tetra Bio-Pharma Announces Results of Artificial Intelligence Study of ARDS-003 Combined with Favipiravir

Tetra Bio-Pharma Inc. Provides Update on Its REDUVO™ New Drug Submission

Tetra Bio-Pharma Inc. and Prepaire Jointly Apply to BARDA for Funding

Tetra Bio-Pharma Inc. announced that it expects to receive CAD 6 million in funding from Alpha Blue Ocean Advisors Ltd

Tetra Bio-Pharma Inc. Announces Positive Preclinical Results of ARDS-003, a Novel Therapeutic for Sepsis and Viral Infections

Recent updates

Tetra Bio-Pharma Inc. Provides Its Shareholders with Another Regulatory Update on the REDUVO™ New Drug Submission

Tetra Bio-Pharma Announces Results of Artificial Intelligence Study of ARDS-003 Combined with Favipiravir

Tetra Bio-Pharma Inc. Provides Update on Its REDUVO™ New Drug Submission

Tetra Bio-Pharma Inc. and Prepaire Jointly Apply to BARDA for Funding

Tetra Bio-Pharma Inc. announced that it expects to receive CAD 6 million in funding from Alpha Blue Ocean Advisors Ltd

Tetra Bio-Pharma Inc. Announces Positive Preclinical Results of ARDS-003, a Novel Therapeutic for Sepsis and Viral Infections

High number of new and inexperienced directors

Tetra Bio-Pharma Inc. Provides Regulatory Update

Tetra Bio-Pharma Inc. Appoints Leslie Auld as Chief Financial Officer

Tetra Bio-Pharma Receives Ema Orphan Drug Designation for A Novel Topical Therapeutic Containing Cbd

Tetra Bio-Pharma Inc. announced that it expects to receive funding from Cannvalate PTY LTD

High number of new and inexperienced directors

Tetra Bio-Pharma Provides Update on Research Collaboration with the University of Montreal Hospital Research Centre for Inhaled CBD

Tetra Bio-Pharma Inc. has completed a Composite Units Offering in the amount of CAD 2.129432 million.

Tetra Bio-Pharma Inc. Announces Positive Initial Clinical Data from its Ongoing Phase 2 Clinical Trials (REBORN©1 and PLENITUDE©) of QIXLEEF™ for Cancer Pain

Tetra Bio-Pharma Accelerates REBORN1© Trial

Significant Discovery Reveals New Antiviral Properties of Tetra Bio- Pharma's Innovative Drug ARDS-003

Independent Chairman of the Board William Cheliak has left the company

Health Canada Accepts New Drug Submission for REDUVO™ as a Treatment for Patients with Chemotherapy-induced Nausea and Vomiting

Independent Director has left the company

Tetra Bio-Pharma Announces Clinical Advancements

Tetra Bio-Pharma Inc. has completed a Composite Units Offering in the amount of CAD 10 million.

Tetra Bio-Pharma Inc. Accelerates Plenitude Clinical Trial to Evaluate the Effect of Cannabis for Use in Managing Uncontrolled Cancer Pain

Tetra Bio-Pharma Announces Start of the Reborn1(C) Clinical Trial

Tetra Bio-Pharma Inc. Re-Activates Veterinary Clinical Study in Companion Animals

Tetra Bio-Pharma Inc., Annual General Meeting, May 28, 2021

Tetra Bio-Pharma Provides Status of its New Drug Submission Application in Canada

Tetra Bio-Pharma Inc. has completed a Composite Units Offering in the amount of CAD 12.54 million.

Tetra Bio-Pharma Inc. (TSX:TBP) entered into a non-binding term sheet to acquire remaining 80% stake in Targeted Pharmaceuticals, LLC for approximately $9.5 million.

New 90-day high: €0.24

Tetra Bio-Pharma Inc. announced that it has received CAD 1.884461 million in funding

Tetra Bio-Pharma Announces FDA Clearance on IND, Allowing U.S. Reborn Clinical Trial to Commence

Tetra Bio-Pharma Inc. announced that it expects to receive CAD 1.894 million in funding

Tetra Bio-Pharma Inc. Completes Investigational New Drug (Ind) -Enabling Toxicology, Clearing the Way for Human Clinical Trials for Its Novel Drug Candidate Ards-003

Tetra Bio-Pharma Inc. Provides Update on Market Potential of ARDS-003

Mondias Natural Products Inc. (TSXV:NHP) completed the acquisition of Lumiera Health Innovation Inc. from Tetra Bio-Pharma Inc. (TSXV:TBP) and certain minority shareholders.

Tetra Bio-Pharma Inc. Unveils Its Commercial Vision on a Robust Chemotherapy Induced Nausea and Vomiting Portfolio

Tetra Bio-Pharma Inc. Enters into A Definitive Agreement with a USA Strategic Partner to Acquire the Canadian Exclusive Rights for Dronabinol Soft Gel Capsules

Tetra Bio-Pharma Inc.(TSXV:TBP) dropped from S&P/TSX Venture Composite Index

Mondias Natural Products Inc. (TSXV:NHP) signed a binding letter of intent to acquire Lumiera Health Innovation Inc. from Tetra Bio-Pharma Inc. (TSXV:TBP) for CAD 1.4 million.